Product Description
Gefitinib Tablets 250mg: What the Published Guidance Says
Cytotoxic and targeted agents spanning the taxane, antifolate and EGFR-tyrosine-kinase-inhibitor classes, supplied with the analytical and stability documentation oncology procurement requires.
Gefitinib Tablets 250mg sits in the Oncology range. The notes below are the ones that most often change a specification, a label or a tender submission.
- EGFR tyrosine-kinase inhibitors and their toxicity profile In its review of non-small cell lung cancer, the WHO Expert Committee recorded that EGFR tyrosine-kinase inhibitors are generally well tolerated, with diarrhoea occurring in more than 60% of patients treated, characteristic dermatological toxicity and rash across the class, and potential hepatic toxicity. Rare but severe gastrointestinal toxicity, including perforation, was noted particularly with erlotinib. WHO EML Expert Committee — Non-small cell lung cancer review
- 2025 extended access to checkpoint inhibitors Pembrolizumab was added to the Model List as first-line monotherapy for metastatic cervical cancer, metastatic colorectal cancer and metastatic non-small cell lung cancer, with atezolizumab and cemiplimab as therapeutic alternatives for the lung indication. WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
- Paclitaxel: premedication is part of the product's use The same review records that paclitaxel is associated with a high incidence of neutropenia, frequently severe, and can cause hypersensitivity reactions in up to 30% of patients, so premedication is required to reduce that risk. Alopecia is described as universal and peripheral neuropathy common, both reversible. WHO EML Expert Committee — Non-small cell lung cancer review
These points are quoted because they shape how Gefitinib Tablets 250mg is specified, labelled and purchased — including strength selection, pack size and the artwork wording. Confirm each one against the approved product information in your market before finalising a purchase order.
Ordering Parameters for Gefitinib Tablets 250mg
| Product Name | Gefitinib Tablets (Gefitinib 250mg Oral Tablets) |
| Specification | Each tablet contains: Gefitinib 250mg |
| Dosage Form | Oral Film-Coated Tablet (for oral administration) |
| Active Ingredient | Gefitinib |
| Pharmacological Class | Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (Targeted Therapy) |
| Route of Administration | Oral administration (swallowed whole with water; may be taken with or without food). Take at approximately the same time each day. |
| Storage | Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze. |
| Therapeutic group | Oncology — Oncology |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Afatinib Dimaleate 40mg Tablets, Erlotinib Hydrochloride 150mg Tablets, Sunitinib Malate 12.5mg Capsules, Pemetrexed Disodium Injection 100mg, Paclitaxel Albumin-Bound 100mg/20mL.
Pharmacopoeial Standard, Release Testing & COA
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Gefitinib Tablets 250mg is released against the pharmacopoeial monograph named on your order (USP, EP, BP or CP). Where no monograph exists for the exact presentation, the specification is agreed with you in writing before manufacture and is attached to the certificate of analysis.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
The quality control package for the marketed pack covers:
- Testing for dissolution or release profile (solid oral forms)
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
- Testing for heavy metals and elemental impurities
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Packing, Labelling Languages & Export Paperwork
- Pack size: Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
- Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
- Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.
Marketing Authorisation & Tender Support
Sinophare Bio-technology Co., Ltd. holds DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. That registration identifies the legal manufacturer on the certificate of analysis, the GMP certificate and the documents filed with your national medicines authority.
- Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
- Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
This page describes Gefitinib Tablets 250mg as a product of the cancer medicines reviewed for the WHO Model List family. A WHO or national listing is a supply-context fact, not an approval in your market; marketing authorisation remains specific to each country.
Gefitinib Tablets 250mg: Common Procurement Questions
What pack size is available for Gefitinib Tablets 250mg?
The reference pack is Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Non-standard blister, bottle and carton configurations are quoted against your artwork, matched to the stability data already held for the presentation.
What documentation comes with a shipment of Gefitinib Tablets 250mg?
Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 36 months.
Does the batch documentation for Gefitinib Tablets 250mg support a registration filing?
Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Why do you publish the WHO toxicity notes?
Because they are part of how this class is used safely. Paclitaxel hypersensitivity and EGFR-inhibitor rash are real clinical facts that procurement and clinical teams should both see on the same page.
Is every product on this page on the WHO Essential Medicines List?
No. Listing status differs by molecule, and the Model List is deliberately narrow. Always confirm the current status of the specific molecule against the Model List and your national essential medicines list rather than relying on general statements.
Products Commonly Ordered with Gefitinib Tablets 250mg
- Afatinib Dimaleate 40mg Tablets — 40mg
- Erlotinib Hydrochloride 150mg Tablets — 150mg
- Sunitinib Malate 12.5mg Capsules — 12.5mg
- Pemetrexed Disodium Injection 100mg — 100mg
- Paclitaxel Albumin-Bound 100mg/20mL — 100mg
Browse the full Oncology range; all Tablets; the complete product catalogue.
Request a Quotation for Gefitinib Tablets 250mg
Send the specification, pack size, quantity and destination market for Gefitinib Tablets 250mg 250mg and we will confirm availability, lead time and documentation. Tender quantities and registration samples are handled on the same quotation.
Sources & Regulatory Notes
- WHO EML Expert Committee — Non-small cell lung cancer review
- WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
